New Research Seeks to Limit MYC Role in B-Cell Lymphomas

According to a study published in the Journal of Clinical Investigation, scientists may have uncovered a previously unknown cell signalling pathway in B-cell lymphoma that could be exploited as an effective treatment path.

The lead author of the study is Andrei Thomas-Tikhonenko, Ph.D., an oncology researcher at The Children's Hospital of Philadelphia.

The discovery is in regards to a familiar family of oncogenes in B-cell lymphoma, known as MYC. MYC codes for myc, a protein that at very high levels kick-starts unceasing cell proliferation.

These researchers looked for proteins on the cell surface and looked at one known as CD19, which is present on the surface of all cells and that is good at recognizing foreign invaders. CD19 is required to stabilize the myc protein, and when stable and found at high levels, it causes cancer. Furthermore, high levels of the Myc protein tend to result in poorer patient outcomes.

Normally when you inhibit one signaling pathway, the cell finds another path, but with CD19 that isn't the case. If you inhibit the CD19 pathway, you can inhibit the levels of the Myc protein.

However, broad-based antibodies that sweep through and kill all cells with certain cell surface receptors are compromising patient immune systems. Thomas-Tikhonenko thinks that the absence of a newly developed pathway for CD19 suggests that specific therapies could exploit this pathway and be much more selective about the cells that are killed, thereby potentially making treatments safer and with fewer side effects.

Source: Medical News Today

b cell lymphoma tretment

More Articles

More Articles

In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. T cell lymphomas account for about...

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

In non-Hodgkin's lymphoma, you have your B-cell lymphomas and you have your T-cell lymphomas.

Why B...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is a relatively rare B-cell subtype of non-Hodgkin'...

T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma. It tends to develop in...

In general, a diagnosis of T-cell lymphoma denotes a poorer prognosis than a diagnosis of B-cell lymphoma. One of...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...